Cellectis Stock Surges 5.34% at Close, Driven by Quarterly Momentum
Cellectis stock closed on Thursday, December 4 at 4.24 euros, up 5.34% from the previous day. This increase occurs in a context of moderate trading volumes representing 0.47% of the capital, while the biotechnology company shows a remarkable three-month performance with a surge of over 90%.
Market Performance and Recent Trends
The stock of the French biotech specializing in genome editing closed at 4.24 euros this Thursday, December 4, marking a 5.34% increase from the previous session where it was priced at 4.03 euros. This rise occurs in a generally favorable Parisian market, with the CAC 40 advancing 0.43% to 8,122.03 points. Trading volumes remained measured with 0.47% of the capital traded. Over the past week, the stock has, however, declined by 3.53%, but this correction seems limited in light of a spectacular quarterly performance of 90.13%. Over one year, Cellectis has jumped 135.6%, significantly outperforming the reference Parisian index which has risen by 11.94% over the same period.
Technical Indicators and Market Position
Technical indicators confirm a medium-term bullish momentum for the stock. The price is significantly above its moving averages, with a 50-day moving average at 3.43 euros and a 200-day at 2.12 euros, respectively 23.6% and 100% below the current level. This configuration indicates a strong underlying trend, although the RSI at 65 suggests a gradual approach to an overbought zone, without yet reaching it. The MACD shows a favorable setup with a MACD line at 0.21 above its signal line at 0.19, and a positive histogram at 0.02 confirming the bullish momentum. Bollinger Bands place the price within a range between 2.72 euros (lower boundary) and 4.90 euros (upper boundary), positioning the day's trading in the upper part of this technical corridor. The stock also trades above its major resistance threshold set at 4.55 euros, potentially paving the way for further gains. The one-month volatility is established at 25.15%, reflecting the broad movements characteristic of biotechnological stocks in the clinical phase.
Technical Environment and Future Outlook
The technical environment appears generally constructive for Cellectis, with a stock that has capitalized on several recent announcements, notably a publication in Nature Communications demonstrating the effectiveness of single-stranded circular DNA as a non-viral template for gene insertion. Oddo BHF has initiated coverage of the stock with an 'outperform' rating and a target of 6.5 euros, representing a potential upside of more than 50% from current levels. The company also has enhanced financial visibility with a treasury of 225 million dollars as of September 30, 2025, compared to 264 million dollars on December 31, 2024. Investors will closely monitor the presentations scheduled at the ASH congress this weekend, which could serve as a new catalyst for the stock if the clinical data prove encouraging. The low beta of 0.27 further confirms the stock's relative disconnection from market movements, a typical characteristic of biotechs whose variations depend primarily on scientific and clinical advancements.
